Lestaurtinib
Lestaurtinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against receptor-type tyrosine-protein kinase FLT3.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
11 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Polycythemia vera | D011087 | D45 | 1 | 2 | — | — | — | 2 | |
Leukemia | D007938 | C95 | 1 | 2 | — | — | — | 2 | |
Primary myelofibrosis | D055728 | D47.4 | 1 | 2 | — | — | — | 2 | |
Thrombocytosis | D013922 | D75.83 | — | 1 | — | — | — | 1 | |
Myeloid leukemia acute | D015470 | C92.0 | — | 1 | — | — | — | 1 | |
Psoriasis | D011565 | EFO_0000676 | L40 | — | 1 | — | — | — | 1 |
Essential thrombocythemia | D013920 | D47.3 | 1 | 1 | — | — | — | 1 | |
Prostatic neoplasms | D011471 | C61 | — | 1 | — | — | — | 1 | |
Myeloid leukemia | D007951 | C92 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neuroblastoma | D009447 | EFO_0000621 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | LESTAURTINIB |
INN | lestaurtinib |
Description | LSM-1231 is an indolocarbazole. |
Classification | Small molecule |
Drug class | tyrosine kinase inhibitors |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O |
Identifiers
PDB | 5WNJ |
CAS-ID | 111358-88-4 |
RxCUI | — |
ChEMBL ID | CHEMBL603469 |
ChEBI ID | — |
PubChem CID | 126565 |
DrugBank | DB06469 |
UNII ID | DO989GC5D1 (ChemIDplus, GSRS) |
Target
Agency Approved
FLT3
FLT3
Organism
Homo sapiens
Gene name
FLT3
Gene synonyms
CD135, FLK2, STK1
NCBI Gene ID
Protein name
receptor-type tyrosine-protein kinase FLT3
Protein synonyms
CD135, CD135 antigen, fetal liver kinase 2, Fetal liver kinase-2, FL cytokine receptor, FLK-2, FLT-3, fms related tyrosine kinase 3, Fms-like tyrosine kinase 3, growth factor receptor tyrosine kinase type III, Stem cell tyrosine kinase 1, STK-1
Uniprot ID
Mouse ortholog
Flt3 (14255)
receptor-type tyrosine-protein kinase FLT3 (Q00342)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,020 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
168 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more